Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Spero Therapeutics, Inc. | spro-ex321_11.htm |
| EX-31.2 - EX-31.2 - Spero Therapeutics, Inc. | spro-ex312_13.htm |
| EX-31.1 - EX-31.1 - Spero Therapeutics, Inc. | spro-ex311_14.htm |
| EX-23.1 - EX-23.1 - Spero Therapeutics, Inc. | spro-ex231_10.htm |
| EX-21.1 - EX-21.1 - Spero Therapeutics, Inc. | spro-ex211_7.htm |
| EX-10.13 - EX-10.13 - Spero Therapeutics, Inc. | spro-ex1013_338.htm |
| EX-10.12 - EX-10.12 - Spero Therapeutics, Inc. | spro-ex1012_337.htm |
| EX-10.6 - EX-10.6 - Spero Therapeutics, Inc. | spro-ex106_372.htm |
| EX-4.3 - EX-4.3 - Spero Therapeutics, Inc. | spro-ex43_371.htm |
| 10-K - 10-K - Spero Therapeutics, Inc. | spro-10k_20191231.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Spero Therapeutics, Inc. (the “Company”) for the period ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
Date: March 16, 2020
|
By: |
/s/ Stephen J. DiPalma |
|
|
Stephen J. DiPalma |
|
|
Interim Chief Financial Officer and Treasurer |
|
|
(Principal Financial Officer and Principal Accounting Officer) |